| 名称 | Betrixaban maleate |
| 描述 | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4]. |
| 激酶实验 | To measure the inhibition of fXa activity by direct fXa inhibitors and the reversal of its inhibitory effect by r-Antidote, purified human plasma fXa (3 nM) (Haematologic Technologies), varying concentrations of inhibitor (0, 2.5, 5.0 and 7.5 nM) and r-Antidote are added to the assay buffer (20 mM Tris, 150 mM NaCl, 5 mM Ca2+ and 0.1% BSA, pH 7.4). After incubation at room temperature for 30 min, 100 μM Spectrozyme-fXa is added to the mixture, and the initial rate of sub?strate cleavage is monitored continuously for 5 min at 405 nm in a 96-well plate reader. The initial velocity of product formation as a function of inhibitor and r-Antidote concentrations is analyzed by Dynafit to estimate the binding affinity of r-Antidote to each inhibitor[2]. . |
| 动物实验 | Whole-blood INR values (mean±s.d.) in rats infused with Betrixaban (1 mg/kg per hour) or vehicle and then treated with either vehicle or r-Antidote by i.v. bolus (6 mg) over 5 min plus infusion (9 mg/h) for up to 90 min. Circles, vehicle+vehicle; squares, Betrixaban + vehicle; triangles, Betrixaban + r-Antidote. *P≤0.02 compared to the r-Antidote treatment group determined by unpaired two-tailed t test. Whole-blood INR values (mean±s.d.) in rats infused with Apixaban (0.5 mg per kg body weight h?1) or vehicle and then treated with either vehicle or r-Antidote by i.v. bolus (6 mg) over 5 min plus infusion (6 mg/h) for up to 90 min. Circles, vehicle + vehicle; squares, apixaban + vehicle; triangles, apixaban+r-Antidote. *P≤0.01 compared to the r-Antidote treatment group determined by unpaired two-tailed t test. |
| 体外活性 | 在膜片夹持hERG实验中，Betrixaban的IC50为8.9 μM。对于Betrixaban，血浆激肽释放酶的IC50和Ki值分别为6.3 μM和3.5 μM。Betrixaban（hERG Ki 1.8 μM）展示的hERG活性显著低于所有其他化合物（hERG Ki≤0.5 μM）。 |
| 体内活性 | 静脉注射（IV）0.5 mg/kg及口服（PO）2.5 mg/kg时，Betrixaban在犬体内的生物利用度为51.6%；静脉注射0.75 mg/kg及口服7.5 mg/kg时，Betrixaban在猴子体内的生物利用度为58.7%[1]。Betrixaban和Apixaban引起的全血国际标准化比值（INR）增加均可被r-Antidote类似地逆转。三种fXa抑制剂（每种分别给药）静脉输注30分钟后，rivaroxaban、Betrixaban和apixaban的总血浆浓度分别为1.4±0.4 μM、0.2±0.01 μM和1.4±0.3 μM，未结合抑制剂的百分比分别为2.2%±0.8%、40%±7.2%和1.5%±0.3%。r-Antidote给药后，抑制剂的总血浆浓度增至1.9±0.09 μM、2.0±0.4 μM和4.2±0.7 μM，未结合抑制剂的百分比降至0%、0.3%±0.1%和0.05%±0.02%。因此，对于这三种抑制剂，r-Antidote将凝血酶原时间修正至接近正常值，与抑制剂的自由分数降低相关联[2]。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 50 mg/mL (88.03 mM)
|
| 关键字 | Inhibitor | PRT 054021 | PRT-054021 | Betrixaban Maleate | Betrixaban | antithrombotic effect | Betrixaban maleate | Factor Xa | Fxa | PRT054021 | inhibit |
| 相关产品 | Heparin sodium salt | 2-Methoxyphenothiazine | Betrixaban | Gabexate mesylate | Coumarin | Apixaban | Edoxaban Tosylate Monohydrate | Edoxaban | 4-Chlorophenylurea | Zifaxaban | Fidexaban | Letaxaban |
| 相关库 | 抑制剂库 | 经典已知活性库 | 已知活性化合物库 | 代谢化合物库 | EMA 上市药物库 | 凝血与抗凝化合物库 | 上市药物库 | FDA 上市药物库 | 药物功能重定位化合物库 | 抗代谢疾病化合物库 |
